A decade of efficiency-driven reform. A readiness gap that has barely moved. A threat environment that has changed completely. These were the three threads woven through every substantive session at the MTEC | Medical Technology Enterprise Consortium‘s 10th Annual Membership Meeting – and together they describe a moment of genuine urgency for anyone building hardware for the next generation of military medicine.
Inertia attended this year’s meeting to understand where the demand signal is sharpest, where the technical gaps are most exposed, and where an integrated product engineering and manufacturing partner can create the most leverage. What we heard confirmed a strategic thesis we have been building for the past year: the battlefield medical system is undergoing a structural transition that the existing industrial base is not equipped to support.
This is our read on what matters most – and what it means for the companies serious about building in this space.
The Readiness Crisis in Plain Terms
Sean O’Keefe, Deputy Assistant Secretary of Defence for Personnel and Readiness, opened the conference with the kind of frankness you rarely hear from a DoD official at a podium. The Military Health System, he argued, has spent a decade optimising for the wrong objective. The 2017 NDAA reforms – well-intentioned, structurally significant – produced a more efficient healthcare system. They did not produce a more ready military medical force. In 2026, roughly 10% of active duty general surgeons meet their Knowledge, Skills, and Abilities threshold. That number is essentially unchanged from when the metric was first introduced.
Staffing is down 13% over ten years. Funding is down 7% in real terms. Beneficiary satisfaction has dropped from the 89th percentile to the 75th. The reforms delivered quality and safety improvements – those gains are real – but on the metric that actually justifies the existence of a military medical system, the needle has not moved.
The Golden Hour model cannot be assumed in a contested peer-adversary environment. Casualties may go unevacuated for not hours, but days.
The stakes of that gap are not abstract. O’Keefe referenced modelling that projects 5,000 preventable deaths in a large-scale conflict if medical readiness is not adequately prioritised. The casualty rate estimates for a peer-adversary conflict – potentially 1,000 per day for 100 days – represent loads not seen since the Second World War. The system built for counterinsurgency operations, where air superiority was assumed and medevac timelines averaged 13 minutes, will not be the system that manages that scale of trauma in a contested environment.
The Paradigm Has Shifted. The Equipment Has Not.
The operational concept at the centre of serveral of the panel discussions was Prolonged Casualty Care. The logic is demanding: when evacuation timelines stretch from minutes to days, you need the capability to sustain a casualty through that window with whatever can be carried forward – not a field hospital, but something that bridges the gap to one.
The SOF medicine panel – which included acquisition leaders and frontline critical care nurses from SOCOM – was the most direct about what this means for hardware. The shift is not incremental. Equipment that was designed for short transport windows is simply inadequate for a multi-day prolonged field care scenario. Ventilators, infusion management, monitoring systems: all of them were designed around assumptions that no longer hold.
The panel’s requirements guidance was specific enough to be acted on:
Devices must sustain autonomous function without power resupply for days, not hours. The SOF medical kit is finite – if a new technology enters the bag, something comes out, and it has to earn that trade by doing more than one job. Size, weight, and power constraints are non-negotiable. Proprietary batteries and cables are an active liability in a logistics environment already managing hundreds of line items. And cognitive burden reduction is the number one design requirement: binary status feedback – green, yellow, red – not raw physiological data requiring clinical interpretation.
A weapons specialist covering a patient overnight should be able to identify that something has changed and act on it without clinical training.
These are not edge cases or aspirational requirements. They are what the end user is asking for, stated clearly at a conference where end users and acquisition officials were in the same room.
Where the Research Is Pointing
The most technically substantive presentation of the meeting came from Colonel (Ret.) Ronald Poropatich, Director of the Centre for Military Medicine Research at the University of Pittsburgh. His team has spent several years building exactly what the operational community is asking for: a portable, ruggedised system capable of autonomous physiological monitoring and closed-loop resuscitation from point of injury through every subsequent echelon of care.
The Mini-ICU concept – a rucksack-deployable hardware stack built around Canada’s Thornhill Medical MOVES SLC ventilator, paired with non-invasive sensors, infusion pumps, and an integrated electronic health record – is the closest thing currently in development to what the SOF panel described as the capability gap. Pittsburgh’s software layer runs closed-loop resuscitation, ventilator control, and continuous physiological monitoring on top of that hardware foundation. Their TRACIR (TRAuma Care In a Rucksack) programme validated autonomous resuscitation in a porcine model of lethal haemorrhagic shock, then demonstrated continuous management through ground transport, air transport, and a multi-hour flight – extending the effective golden hour to approximately five hours. The follow-on CRUISE (Cardiovascular Resuscitation Using Informed Semi-Closed Loop) programme advances this to non-invasive hemodynamic monitoring, making it genuinely deployable in uncontrolled field conditions.
The RAPTER (Rapid Assessment for Prehospital Triage of Evacuation and medical Resources) triage AI – trained on 15,000 patient episodes, capable of predicting required life-saving interventions 15 minutes before they occur – sits at the other end of the same system. It runs on wearables, takes two-minute assessments at 30-minute intervals, and is designed to be interpreted by non-specialists.
What Poropatich’s work illustrates is how far the research has advanced – and how much of the gap between validated prototype and fielded system remains an engineering and manufacturing problem rather than a science problem. The algorithms exist. The sensing capability exists. The autonomous movement platforms, validated operationally in Ukraine, are proliferating. What the space is missing is the product engineering capability to integrate these components into ruggedised, manufacturable, certifiable systems that can survive the acquisition pathway and reach the field.
Ukraine as the Live Reference Case
Every panel that addressed the operational environment eventually returned to Ukraine. Not as a distant data point, but as a live laboratory that has resolved several of the theoretical debates that used to frame these conversations.
Drone proliferation has eliminated the safe rear area. Medical personnel are now exposed to the same targeting as front-line combatants. Medical evacuation vehicles are high-value targets. Casualty collection points must be buried underground to survive incoming strikes. The Geneva Convention provides no protection. Average evacuation wait times in some sectors have reached a week; some casualties have waited a month.
By 2024, approximately 30% of evacuation vehicles along the eastern front were unmanned ground vehicles – a proportion that is growing. The FOXTAC medevac UGV, a 40 cm profile tracked platform developed under Ukraine’s Brave1 defence-tech initiative, was formally approved for battlefield use in September 2024. The operational validation of autonomous medical evacuation is no longer theoretical. It is documented, ongoing, and scaling.
The practical implication for hardware developers is that any solution which creates electronic signature, physical bulk, or reduced mobility for a medical team represents a tactical liability. This is not a constraint that can be designed around after the fact. It has to be the foundational design assumption.
What the Acquisition System Will and Will Not Reward
The awardee panel and the investor session both reinforced a set of realities about how technology actually moves through the defence acquisition system – realities that are easy to underestimate from outside the process.
Programme offices have seen most ideas before. The companies that win awards are not necessarily the ones with the best technology. They are the ones who understood the specific capability gap the programme office was trying to close, who could articulate their transition thesis clearly, and who came in asking the right questions – what has failed before, what is the programme office measured on, what does success look like at each TRL milestone.
The SOCOM acquisition structure is worth understanding specifically. SOCOM does not have the advanced development funding to drive technologies across the finish line independently. Its value is as an early adopter: high operational tempo, tolerance for risk, real-world validation environments. Technologies that get validated through SOCOM then scale through conventional force and Defence Health Agency channels. Pitching exclusively to SOCOM without a broader adoption pathway is a constrained strategy.
On the investor side, J2 Ventures’ Matt Goldman named physical AI – the next generation of medical robotics and autonomous systems – as his highest-conviction area, citing the maturation of sensor hardware and AI inference as the enabling factors. The dual-use framing matters here: the same system that stabilises a casualty in a contested environment stabilises a trauma patient in a rural hospital with no specialist available. When that translation is made clearly, investors respond to it.
The SBIR pathway offers one structural advantage worth noting: any product that derives from an SBIR award is considered competitively sourced for direct military procurement, allowing smaller companies to sell to the military without a full competitive tender. That advantage disappears if the company cannot actually manufacture at scale – a gap that kills more promising technologies than regulatory failure.
The Engineering Gap Nobody Is Talking About
The conference was dense with clinical insight, acquisition guidance, and research validation. What was largely absent was a serious conversation about the engineering challenge of getting from validated prototype to fielded product.
Prolonged Casualty Care systems are not straightforward products. They require the integration of electromechanical systems, embedded software, ruggedised enclosures, power management under extreme SWaP constraints, medical-grade sensor arrays, and autonomous control algorithms – all certified for use in environments ranging from Arctic cold to high altitude to underwater-adjacent humidity. The manufacturing challenge is equally complex: these are low-volume, high-mix products with exacting reliability requirements and supply chains that have to survive the same contested environment the product is designed for.
Most of the companies presenting at MTEC are deep in one dimension of that problem. The research teams have the algorithms. The device companies have individual validated components. The software platforms have the decision support layer. What is missing, in most cases, is the integrated product engineering and manufacturing capability to assemble these elements into a cohesive, certifiable, manufacturable system.
The algorithms exist. The sensing capability exists. What the space is missing is the product engineering capability to integrate these components into ruggedised, manufacturable, certifiable systems.
There is a third dimension that compounds the first two: regulatory navigation. Closed-loop autonomous resuscitation systems that make treatment decisions without a physician present occupy genuinely unresolved regulatory territory. The civilian FDA pathway was not designed for them. The US DoD has exception mechanisms – Emergency Use Authorisations, Investigational New Drug applications, and the enhanced DoD-FDA engagement framework established under P.L. 115-92 – and the SOF panel was explicit that those mechanisms need to be on the table. But knowing how to move a system through those pathways, and how to structure development programmes so that military exception mechanisms don’t foreclose civilian market access later, is itself a specialised capability that most hardware teams don’t have in-house.
That gap is where Inertia operates. The shift from Golden Hour to Prolonged Casualty Care is not primarily a science problem or a policy problem at this point. It is an engineering, manufacturing, and regulatory navigation problem – and the companies that can close all three will define the next generation of military medical systems.
What This Means Going Forward
The MTEC meeting made the demand signal as clear as we have seen it. The DoD has declared readiness the explicit top priority. The FY2027 budget has been structured to separate combat medicine funding from routine healthcare delivery – a structural signal of intent, not just rhetoric. The operational community has named its requirements with unusual specificity. The research community has validated autonomous resuscitation and triage AI at preclinical levels. Ukraine has validated the autonomous evacuation platform in live combat.
The question for hardware companies, research institutions, and integrators is no longer whether this market is real. It is whether they can build the systems it requires – at the quality level, the reliability level, and the production scale that getting to the field actually demands.
For Canadian industry (where we are located), the question is sharper. Canada’s own defence health documents are candid about the same readiness gap O’Keefe described: CFHS MEDEVAC capability falls well short of NATO commitments, prolonged casualty care requirements are expected to grow in the Future Operating Environment, and the shortfalls are documented and unresolved. Canada is now committing serious capital to defence modernisation – $81.8 billion over five years announced in Budget 2025 – but the doctrine and the technology requirements for the next generation of military medical systems are being written in Washington, validated in Ukraine, and funded through US acquisition mechanisms. Canadian companies that want to shape those outcomes rather than inherit them need to be engaged now. The proof of concept exists: Toronto’s Thornhill Medical built a portable ICU that is embedded in US Navy carrier strike groups and deployed on the eastern front in Ukraine. That is not a coincidence of geography. It is the result of a deliberate decision to engage the US DoD market early, on its terms, with a product engineered to meet its requirements. The path is open.
The window for positioning is open. It will not stay open indefinitely.
Inertia Group is a Toronto-based product strategy, engineering, and manufacturing partner for complex hardware, medical devices, and advanced electromechanical systems. We work with scaling hardware companies, regulated product manufacturers, and OEMs to turn complex product challenges into manufacturable, launch-ready outcomes.
